Hospital
Prospect CCMC, LLC
Prospect CCMC, LLC was paid $40.89M by Medicaid between Jan 2018 and Dec 2024, across 246 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoPROSPECT CCMC, LLC
CHESTER, PA 19013
CHESTER, PA 19013
33aNPI1457715146assigned 04/08/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$40.89M
24GClaims310,908
24DCodes billed246
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#4 of 154
Median peer was paid$2.82M
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ELDERS, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,557 | $154K | |
| 2019 | 5,744 | $513K | |
| 2020 | 44,876 | $4.86M | |
| 2021 | 110,798 | $15.81M | |
| 2022 | 33,950 | $6.38M | |
| 2023 | 53,849 | $7.46M | |
| 2024incomplete | 60,134 | $5.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 32,840 | 31,507 | $9.85M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 25,178 | 24,138 | $7.20M |
| G0378 | Hospital observation service, per hour | 17% | 3,162 | 2,848 | $7.06M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 26,203 | 24,949 | $6.90M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.2% | 6,173 | 5,908 | $1.71M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 1.9% | 2,154 | 1,891 | $756K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 1.5% | 1,503 | 1,343 | $603K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 2,060 | 1,932 | $579K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,109 | 2,975 | $387K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,566 | 2,183 | $294K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,547 | 1,531 | $280K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 914 | 897 | $231K |
234 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,221 | $215K |
| 62323 | <1% | 130 | $203K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,352 | $173K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 307 | $166K |
| 59025 | Fetal non-stress test | <1% | 2,684 | $164K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,041 | $162K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,495 | $152K |
| 97597 | <1% | 1,092 | $147K | |
| 97161 | <1% | 578 | $142K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,015 | $136K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,246 | $133K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,627 | $128K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 158 | $122K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 239 | $118K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 312 | $109K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 769 | $100K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,241 | $95K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 155 | $84K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,002 | $80K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,534 | $75K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,947 | $74K |
| 76830 | Ultrasound, transvaginal | <1% | 665 | $73K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,153 | $65K |
| 76801 | <1% | 663 | $60K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,996 | $58K |
| 77066 | Tomosynthesis, mammo | <1% | 293 | $53K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,342 | $52K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 451 | $51K |
| 74183 | <1% | 53 | $50K | |
| 76536 | <1% | 364 | $49K | |
| 97164 | <1% | 482 | $45K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 638 | $45K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,242 | $44K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,924 | $44K |
| 72100 | <1% | 675 | $43K | |
| 76813 | <1% | 301 | $42K | |
| 93971 | <1% | 329 | $42K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 291 | $42K |
| 76642 | <1% | 424 | $41K | |
| 73564 | <1% | 862 | $41K | |
| 97010 | <1% | 2,170 | $38K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 297 | $38K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 310 | $36K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,398 | $36K |
| 93017 | <1% | 311 | $36K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,266 | $35K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 111 | $35K |
| 71250 | <1% | 250 | $34K | |
| 97162 | <1% | 498 | $32K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 783 | $32K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,236 | $32K |
| 80053 | Comprehensive metabolic panel | <1% | 8,667 | $31K |
| 93970 | <1% | 158 | $30K | |
| 0002A | <1% | 521 | $29K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 91 | $27K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 260 | $27K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 25 | $25K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 271 | $25K |
| 76820 | <1% | 289 | $25K | |
| 73030 | <1% | 659 | $24K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 324 | $23K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,909 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,587 | $22K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 17 | $21K |
| 76770 | <1% | 196 | $20K | |
| 77065 | Tomosynthesis, mammo | <1% | 161 | $20K |
| 73630 | <1% | 684 | $17K | |
| 73610 | <1% | 463 | $16K | |
| 72141 | <1% | 33 | $16K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 392 | $15K |
| 73502 | <1% | 319 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,564 | $14K |
| 77080 | <1% | 146 | $14K | |
| 72040 | <1% | 278 | $14K | |
| 73562 | <1% | 308 | $14K | |
| 73221 | <1% | 30 | $14K | |
| 73560 | <1% | 328 | $14K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 212 | $13K |
| 87631 | <1% | 382 | $13K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 75 | $12K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,371 | $12K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 513 | $11K |
| 73130 | <1% | 404 | $11K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 75 | $11K |
| 93923 | <1% | 68 | $11K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 28 | $11K |
| 01999 | <1% | 301 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,868 | $10K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,880 | $10K |
| 70486 | <1% | 95 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 389 | $9K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 882 | $9K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 836 | $9K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 228 | $8K |
| 73110 | <1% | 257 | $7K | |
| 97598 | <1% | 82 | $7K | |
| 81025 | <1% | 2,400 | $7K | |
| 97166 | <1% | 115 | $7K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 632 | $6K |
| 72072 | <1% | 93 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,545 | $6K |
| 84484 | <1% | 3,339 | $6K | |
| 0001A | <1% | 395 | $6K | |
| 90715 | <1% | 158 | $6K | |
| J3490 | Unclassified drugs | <1% | 5,255 | $5K |
| A0425 | Ground mileage, per statute mile | <1% | 2,863 | $5K |
| 97803 | <1% | 81 | $5K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,507 | $4K |
| 83735 | <1% | 1,995 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 53 | $4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 292 | $4K |
| 85730 | <1% | 1,959 | $4K | |
| 92588 | <1% | 34 | $4K | |
| 95886 | <1% | 25 | $4K | |
| 97113 | <1% | 42 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 479 | $4K |
| 73080 | <1% | 144 | $4K | |
| 72110 | <1% | 49 | $3K | |
| 85027 | <1% | 930 | $3K | |
| 74246 | <1% | 31 | $3K | |
| 97016 | <1% | 129 | $3K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 219 | $3K |
| 85610 | <1% | 2,183 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 160 | $3K |
| 80061 | Lipid panel | <1% | 275 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 220 | $3K |
| C1769 | Guide wire | <1% | 172 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 480 | $2K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 40 | $2K |
| 83690 | <1% | 1,868 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 837 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 233 | $2K |
| 93880 | <1% | 12 | $2K | |
| 97802 | <1% | 35 | $2K | |
| 83880 | <1% | 548 | $2K | |
| 86900 | <1% | 486 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 998 | $2K |
| 81001 | <1% | 2,650 | $2K | |
| 97014 | <1% | 85 | $2K | |
| 20552 | <1% | 17 | $2K | |
| 86850 | <1% | 430 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,004 | $2K |
| 87481 | <1% | 141 | $2K | |
| 72050 | <1% | 24 | $2K | |
| 84703 | <1% | 539 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 521 | $2K |
| 83605 | <1% | 616 | $2K | |
| 95806 | <1% | 13 | $2K | |
| 80320 | <1% | 205 | $2K | |
| 94060 | <1% | 26 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 118 | $1K |
| 73590 | <1% | 53 | $1K | |
| 97168 | <1% | 12 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 229 | $1K |
| 84100 | <1% | 851 | $1K | |
| 92567 | <1% | 36 | $1K | |
| 96367 | <1% | 16 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,302 | $1K |
| 86901 | <1% | 447 | $1K | |
| 97116 | <1% | 244 | $1K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 25 | $920.86 |
| 82550 | <1% | 341 | $903.21 | |
| 74018 | <1% | 39 | $886.45 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,208 | $822.05 |
| 97165 | <1% | 45 | $814.67 | |
| 72202 | <1% | 14 | $786.15 | |
| 81003 | <1% | 683 | $760.08 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 675 | $728.14 |
| 97018 | <1% | 43 | $709.96 | |
| 73620 | <1% | 22 | $699.54 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,767 | $683.12 |
| 87040 | <1% | 188 | $657.16 | |
| 84702 | <1% | 132 | $643.23 | |
| 82077 | <1% | 312 | $634.29 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 54 | $579.94 |
| J2704 | Injection, propofol, 10 mg | <1% | 650 | $520.61 |
| 87088 | <1% | 258 | $471.07 | |
| 76882 | <1% | 15 | $458.04 | |
| 80051 | <1% | 55 | $453.76 | |
| A0432 | Paramedic intercept (pi), rural area, transport furnished by a volunteer ambulance company which is prohibited by state law from billing third party payers | <1% | 15 | $446.12 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,906 | $431.50 |
| 87641 | <1% | 96 | $426.08 | |
| 73140 | <1% | 16 | $415.19 | |
| 85379 | <1% | 207 | $384.95 | |
| 87186 | <1% | 192 | $341.13 | |
| 87511 | <1% | 121 | $336.31 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 353 | $314.97 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,027 | $301.42 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 850 | $281.23 |
| 87800 | <1% | 38 | $240.28 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $223.30 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,204 | $223.13 |
| 99152 | <1% | 12 | $207.09 | |
| 80329 | <1% | 27 | $202.15 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 906 | $196.68 |
| 87077 | <1% | 132 | $178.46 | |
| 96376 | <1% | 375 | $164.69 | |
| 82565 | <1% | 66 | $155.85 | |
| 84520 | <1% | 67 | $149.11 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 431 | $140.86 |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 310 | $136.17 |
| 82947 | <1% | 53 | $98.83 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 473 | $82.99 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 292 | $68.03 |
| 87205 | <1% | 13 | $65.97 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,037 | $52.47 |
| 86140 | <1% | 50 | $35.46 | |
| 85652 | <1% | 28 | $29.19 | |
| 36416 | <1% | 53 | $12.96 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 12 | $4.45 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 451 | $3.62 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 238 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 350 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 98 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 948 | $0.00 |
| 94664 | 0% | 32 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 85 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 612 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 124 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 91 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 51 | $0.00 |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | 0% | 21 | $0.00 |
| 80143 | 0% | 26 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 28 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 141 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 456 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 69 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 90 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 44 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 15 | $0.00 |
| A0888 | Noncovered ambulance mileage, per mile (e.g., for miles traveled beyond closest appropriate facility) | 0% | 136 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 17 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 20 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialELDERS, ROBERT (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.